Veracyte Company Profile (NASDAQ:VCYT)

About Veracyte

Veracyte logoVeracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company's commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VCYT
  • CUSIP:
Key Metrics:
  • Previous Close: $7.89
  • 50 Day Moving Average: $7.63
  • 200 Day Moving Average: $7.12
  • 52-Week Range: $4.21 - $8.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.55
  • P/E Growth: 0.00
  • Market Cap: $220.53M
  • Outstanding Shares: 27,950,000
  • Beta: 2
  • Net Margins: -57.45%
  • Return on Equity: -88.36%
  • Return on Assets: -46.01%
  • Debt-to-Equity Ratio: 0.83%
  • Current Ratio: 4.18%
  • Quick Ratio: 3.85%
Additional Links:
Companies Related to Veracyte:

Analyst Ratings

Consensus Ratings for Veracyte (NASDAQ:VCYT) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.25 (41.51% upside)

Analysts' Ratings History for Veracyte (NASDAQ:VCYT)
DateFirmActionRatingPrice TargetDetails
2/18/2017Cantor FitzgeraldSet Price TargetBuy$13.00View Rating Details
11/29/2016Janney Montgomery ScottUpgradeNeutral -> BuyView Rating Details
11/22/2016Leerink SwannReiterated RatingBuy$12.00View Rating Details
10/18/2016William BlairReiterated RatingOutperformView Rating Details
8/4/2016Piper Jaffray CompaniesReiterated RatingOverweight$12.00 -> $10.00View Rating Details
6/13/2016BTIG ResearchReiterated RatingBuy$10.00View Rating Details
11/19/2015StephensReiterated RatingBuyView Rating Details
10/14/2015Cowen and CompanyLower Price TargetOutperform$12.00 -> $8.00View Rating Details
3/20/2015Morgan StanleyReiterated RatingEqual Weight$9.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Veracyte (NASDAQ:VCYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q416($0.26)$17.49 millionN/AView Earnings Details
11/3/2016Q316($0.36)($0.20)$15.76 million$18.60 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.40)$14.80 million$14.68 millionViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.36)$13.08 million$13.55 millionViewN/AView Earnings Details
3/10/2016Q415($0.30)($0.29)$14.45 million$14.04 millionViewListenView Earnings Details
11/5/2015Q315($0.33)($0.32)$12.72 million$12.33 millionViewListenView Earnings Details
8/13/2015Q215($0.31)($0.35)$12.23 million$11.90 millionViewListenView Earnings Details
5/14/2015Q115($0.37)($0.34)$10.83 million$11.20 millionViewListenView Earnings Details
3/19/2015Q414($0.33)($0.36)$11.83 million$12.20 millionViewN/AView Earnings Details
11/13/2014Q314($0.35)($0.37)$9.67 million$9.80 millionViewN/AView Earnings Details
8/13/2014Q214($0.33)($0.31)$9.36 million$8.70 millionViewN/AView Earnings Details
5/8/2014Q114($0.31)($0.32)$7.19 million$7.50 millionViewN/AView Earnings Details
3/18/2014Q4($0.38)($0.42)$6.43 million$6.84 millionViewListenView Earnings Details
11/25/2013Q313($6.59)$3.20 million$5.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Veracyte (NASDAQ:VCYT)
Current Year EPS Consensus Estimate: $-1.23 EPS
Next Year EPS Consensus Estimate: $-0.93 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.31)($0.31)($0.31)
Q2 20161($0.28)($0.28)($0.28)
Q3 20161($0.37)($0.37)($0.37)
Q4 20162($0.33)($0.21)($0.27)
Q1 20171($0.19)($0.19)($0.19)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.20)($0.20)($0.20)
Q4 20171($0.23)($0.23)($0.23)
Q1 20181($0.20)($0.20)($0.20)
Q2 20181($0.18)($0.18)($0.18)
Q3 20181($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)


Dividend History for Veracyte (NASDAQ:VCYT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Veracyte (NASDAQ:VCYT)
Insider Ownership Percentage: 28.40%
Institutional Ownership Percentage: 47.50%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/3/2016Bonnie H AndersonCEOBuy5,000$5.40$27,000.00View SEC Filing  
6/1/2016Bonnie H AndersonCEOBuy5,000$5.46$27,300.00View SEC Filing  
5/31/2016Bonnie H AndersonCEOBuy2,500$5.46$13,650.00View SEC Filing  
11/25/2015Evan/ Fa JonesDirectorSell7,896$7.23$57,088.08View SEC Filing  
11/24/2015Evan/ Fa JonesDirectorSell7,104$7.20$51,148.80View SEC Filing  
7/22/2015Christopher M HallCOOSell2,500$11.85$29,625.00View SEC Filing  
6/26/2015Shelly D GuyerCFOSell1,000$12.08$12,080.00View SEC Filing  
9/10/2014Christopher M HallInsiderSell1,000$12.29$12,290.00View SEC Filing  
9/9/2014Evan/ Fa JonesDirectorSell27,304$12.60$344,030.40View SEC Filing  
8/18/2014Christopher M HallInsiderSell1,000$12.92$12,920.00View SEC Filing  
7/29/2014Julie BrooksEVPBuy1,122$14.69$16,482.18View SEC Filing  
7/28/2014Julie BrooksEVPBuy1,000$14.71$14,710.00View SEC Filing  
7/22/2014Julie BrooksVPBuy2,000$14.18$28,360.00View SEC Filing  
7/21/2014Julie BrooksVPBuy1,000$14.00$14,000.00View SEC Filing  
7/10/2014Christopher M HallInsiderSell3,000$14.92$44,760.00View SEC Filing  
6/27/2014Bonnie H AndersonCEOSell1,000$17.95$17,950.00View SEC Filing  
6/23/2014Bonnie H AndersonCEOSell4,000$16.45$65,800.00View SEC Filing  
6/23/2014Christopher M HallInsiderSell2,000$16.95$33,900.00View SEC Filing  
6/20/2014Shelly D GuyerCFOSell1,250$16.04$20,050.00View SEC Filing  
6/19/2014Christopher M HallInsiderSell3,000$14.99$44,970.00View SEC Filing  
6/12/2014Evan/ Fa JonesDirectorSell16,650$15.07$250,915.50View SEC Filing  
6/9/2014Evan/ Fa JonesDirectorSell22,870$14.57$333,215.90View SEC Filing  
6/5/2014Evan/ Fa JonesDirectorSell28,248$14.33$404,793.84View SEC Filing  
5/30/2014Evan/ Fa JonesDirectorSell23,882$15.33$366,111.06View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Veracyte (NASDAQ:VCYT)
DateHeadline logoVeracyte Announces Ten New Blues Plan Coverage Policies for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis (NASDAQ:VCYT) - February 21 at 4:25 PM logoVeracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2016 Financial Results on Wednesday, March 1, 2017 (NASDAQ:VCYT) - February 17 at 5:58 AM logoVeracyte (VCYT) Down as Access for Afirma Broadened (NASDAQ:VCYT) - February 9 at 6:31 AM logoVeracyte (VCYT) Announces Final Medicare Coverage Policies for Percepta (NASDAQ:VCYT) - February 7 at 3:49 PM logoVeracyte Announces Final Medicare Coverage Policies for Percepta® Bronchial Genomic Classifier (NASDAQ:VCYT) - February 6 at 10:24 AM logoVeracyte to Present at LEERINK Partners 6th Annual Global Healthcare Conference (NASDAQ:VCYT) - February 3 at 6:35 AM logoNotable Thursday Option Activity: WRLD, YELP, VCYT (NASDAQ:VCYT) - January 28 at 7:32 AM
News IconVeracyte Inc VCYT Medical Equipment Deals and Alliances Profile Prices from USD $250 (NASDAQ:VCYT) - January 16 at 8:23 PM
News IconCommit To Buy Veracyte At $5, Earn 18.8% Annualized Using Options (NASDAQ:VCYT) - December 24 at 7:52 PM logoETFs with exposure to Veracyte, Inc. : December 22, 2016 (NASDAQ:VCYT) - December 23 at 3:47 AM logoVeracyte : Announces Appointment of Kevin K. Gordon and Other Changes to Its Board of Directors (NASDAQ:VCYT) - December 14 at 8:29 AM logoVeracyte Announces Appointment of Kevin K. Gordon and Other Changes to Its Board of Directors (NASDAQ:VCYT) - December 13 at 11:23 AM logo8:12 am Veracyte Chairman Brian Atwood to step down from the board; co's president and CEO Bonnie Anderson has assumed the additional role of chairman, effective immediately (NASDAQ:VCYT) - December 13 at 11:23 AM
News IconNewly released market study: Medical Device Connectivity Market - Forecast to 2021 (NASDAQ:VCYT) - November 29 at 12:40 PM logoEdited Transcript of VCYT earnings conference call or presentation 3-Nov-16 8:30pm GMT (NASDAQ:VCYT) - November 29 at 12:40 PM
News IconIndependent Bank Group Inc. (IBTX) CEO Sells $550000.00 in Stock (NASDAQ:VCYT) - November 27 at 10:02 AM logoVeracyte (VCYT) Announces CMS Will Maintain Reimbursement Rate for Afirma GEC (NASDAQ:VCYT) - November 23 at 11:37 AM
News IconVeracyte Announces that CMS Will Maintain Historic Medicare Reimbursement Rate for the Afirma® Gene Expression Classifier in... (NASDAQ:VCYT) - November 23 at 11:37 AM logoVeracyte Announces that CMS Will Maintain Historic Medicare Reimbursement Rate for the Afirma® Gene Expression Classifier in 2017 (NASDAQ:VCYT) - November 22 at 12:59 PM logoVERACYTE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:VCYT) - November 21 at 8:45 PM logoVeracyte to Participate in Two Upcoming Investor Conferences (NASDAQ:VCYT) - November 15 at 11:58 AM logoVeracyte, Inc. :VCYT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 (NASDAQ:VCYT) - November 7 at 12:31 PM logoVeracyte reports 3Q loss (NASDAQ:VCYT) - November 3 at 8:13 PM logoQ3 2016 Veracyte Inc Earnings Release - After Market Close (NASDAQ:VCYT) - November 3 at 12:34 PM logoVeracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock (NASDAQ:VCYT) - November 2 at 11:56 AM logoVeracyte Announces Proposed Public Offering of Common Stock (NASDAQ:VCYT) - November 1 at 8:21 PM logoVERACYTE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:VCYT) - November 1 at 8:21 PM logoNew Data Show that Use of Percepta® Bronchial Genomic Classifier Reduces Surgeries and Other Costly Procedures in Lung Cancer Screening and Diagnosis (NASDAQ:VCYT) - October 26 at 7:56 PM logoVeracyte Announces Launch of Envisia™ Genomic Classifier for Improved Diagnosis of Idiopathic Pulmonary Fibrosis at CHEST Annual Meeting 2016 (NASDAQ:VCYT) - October 25 at 8:02 PM logoVERACYTE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:VCYT) - October 19 at 7:34 PM logoETF’s with exposure to Veracyte, Inc. : October 18, 2016 (NASDAQ:VCYT) - October 18 at 7:46 PM logoVeracyte (VCYT) Offers Prelim. Q3 Results (NASDAQ:VCYT) - October 18 at 7:46 AM logoVeracyte Releases Preliminary Third Quarter 2016 Financial Results (NASDAQ:VCYT) - October 17 at 7:50 PM logoVeracyte : Data Demonstrating Clinical Value of Veracyte Genomic Tests for Use in Lung Cancer and IPF to Be Presented at CHEST Annual Meeting 2016 (NASDAQ:VCYT) - October 13 at 8:10 PM logoData Demonstrating Clinical Value of Veracyte Genomic Tests for Use in Lung Cancer and IPF to Be Presented at CHEST Annual Meeting 2016 (NASDAQ:VCYT) - October 13 at 11:58 AM logoDEPO Wins Patent Suit, EBS Surges On BARDA Funding, REGN''s Eylea Combo Fails (NASDAQ:VCYT) - October 4 at 7:31 AM logoVERACYTE, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (NASDAQ:VCYT) - October 3 at 7:22 PM logoVeracyte Releases Statement on CMS's Final 2017 Gapfill Rate for the Afirma® Gene Expression Classifier (NASDAQ:VCYT) - September 30 at 7:11 PM
News IconVeracyte announces new data suggesting ability of Afirma GEC in thyroid cancer diagnosis (NASDAQ:VCYT) - September 26 at 8:47 AM logoVeracyte (VCYT) Announces Positive Data on Afirma in Thyroid Cancer Diagnosis (NASDAQ:VCYT) - September 23 at 7:18 PM
News IconVeracyte Presents Data Demonstrating Potential to Enhance Afirma® Gene Expression Classifier Using an RNA Sequencing Platfor... (NASDAQ:VCYT) - September 23 at 7:18 PM logoVeracyte Presents Data Demonstrating Potential to Enhance Afirma® Gene Expression Classifier Using an RNA Sequencing Platform (NASDAQ:VCYT) - September 23 at 7:18 PM logoVeracyte (VCYT) Announces Palmetto GBA Posting of Draft LCD for Percepta Bronchial Genomic Classifier (NASDAQ:VCYT) - September 16 at 11:35 AM logoVeracyte Secures Draft Medicare Local Coverage Determination for Percepta® Bronchial Genomic Classifier from Palmetto GBA (NASDAQ:VCYT) - September 15 at 8:02 PM logoVeracyte (VCYT) to Present Afirma GEC Data at ATA Meeting (NASDAQ:VCYT) - September 15 at 11:42 AM logoVeracyte Announces Data from Seven Afirma® Gene Expression Classifier Studies to Be Presented at the 86th Annual Meeting of the American Thyroid Association (NASDAQ:VCYT) - September 15 at 11:42 AM
News IconNegative Day for Wall Street (NASDAQ:VCYT) - September 9 at 7:39 AM logoVeracyte (VCYT) Receives LCD from Major MAC for Percepta Bronchial Genomic Classifier (NASDAQ:VCYT) - September 8 at 7:35 PM logo7:38 am Veracyte announces that Noridian Healthcare Solutions has issued a draft local coverage determination for the Percepta Bronchial Genomic Classifier (NASDAQ:VCYT) - September 8 at 11:51 AM logoVeracyte Achieves Major Medicare Coverage Milestone for the Percepta® Classifier to Improve Lung Cancer Diagnosis (NASDAQ:VCYT) - September 8 at 11:51 AM


What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Where is Veracyte's stock going? Where will Veracyte's stock price be in 2017?

6 brokers have issued twelve-month price targets for Veracyte's stock. Their forecasts range from $10.00 to $13.00. On average, they anticipate Veracyte's share price to reach $11.25 in the next twelve months.

When will Veracyte announce their earnings?

Veracyte is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Veracyte stock?

Here are some recent quotes from research analysts about Veracyte stock:

  • According to Zacks Investment Research, "Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. " (2/24/2017)

  • Leerink Swann analysts commented, "We reiterate our OP rating and maintain our PT of $12. Commercial Payers Still Key to Driving Adoption Ramp and Sales Longer-term. VCYT has successfully driven the Afirma adoption ramp by gaining multi-year commercial payer contracts on the back of solid clinical evidence — as 80% of Afirma volumes still comes from private payers. Afirma currently has 185M lives covered and $155M contracted with 25M of those lives in Blue Cross Blue Shield. Beyond that, for Afirma GEC, VCYT’s key priorities include securing a positive coverage decision for the largest Blues payer: Anthem (ANTM, OP) with its 40M covered lives, and converting other Blues payers to in-network contracts. Medicare accounts for only 20% of Afirma test samples and thus the eliminated impact was only ~$1.6M. Plus, with the new data that was released at the ATA meeting recently highlighting 70%-80% of specificity of the enhanced Afirma test, we believe VCYT should be able to get Anthem as well." (11/22/2016)

Who owns Veracyte stock?

Veracyte's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (8.06%), Broadfin Capital LLC (6.40%), Stonepine Capital Management LLC (3.47%), First Light Asset Management LLC (2.48%), Federated Investors Inc. PA (1.88%) and Axiom International Investors LLC DE (1.03%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Shelly D Guyer.

Who sold Veracyte stock? Who is selling Veracyte stock?

Veracyte's stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates.

Who bought Veracyte stock? Who is buying Veracyte stock?

Veracyte's stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Stonepine Capital Management LLC, Axiom International Investors LLC DE, First Light Asset Management LLC, Numeric Investors LLC, Oxford Asset Management, Denver Investment Advisors LLC and ARK Investment Management LLC.

How do I buy Veracyte stock?

Shares of Veracyte can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Veracyte stock cost?

One share of Veracyte stock can currently be purchased for approximately $7.95.

Veracyte (NASDAQ:VCYT) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Earnings History Chart

Earnings by Quarter for Veracyte (NASDAQ:VCYT)

Dividend History Chart

Dividend Payments by Quarter for Veracyte (NASDAQ:VCYT)

Last Updated on 2/24/2017 by Staff